The global market for Bi-Specific Antibodies Therapy was estimated to be worth US$ 3266 million in 2023 and is forecast to a readjusted size of US$ 17140 million by 2030 with a CAGR of 26.4% during the forecast period 2024-2030.

Bi-Specific Antibodies Therapy Market

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.

North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bi-Specific Antibodies Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bi-Specific Antibodies Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Market Segmentation

Scope of Bi-Specific Antibodies Therapy Market Report

Report Metric	Details
Report Name	Bi-Specific Antibodies Therapy Market
Forecasted market size in 2030	US$ 17140 million
CAGR	26.4%
Forecasted years	2024 - 2030
Segment by Type	Fragment-Based Antibodies IgG-Based Antibodies
Segment by Application	Cancer Haemophilia Other Non-Cancer Diseases
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech, MacroGenics, Inc, Genmab, Alphamab Co. Ltd, Akeso, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Bi-Specific Antibodies Therapy in global and regional level.
Chapter 3: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bi-Specific Antibodies Therapy revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

FAQ for this report

What is the Bi-Specific Antibodies Therapy Market size in 2030?

Ans: The Bi-Specific Antibodies Therapy Market size in 2030 will be US$ 17140 million.

What is the market share of major companies in Bi-Specific Antibodies Therapy Market?

Ans: Global top five manufacturers hold a share over 95%.

What is the Bi-Specific Antibodies Therapy Market share by type?

Ans: In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%.

Who are the main players in the Bi-Specific Antibodies Therapy Market report?

Ans: The main players in the Bi-Specific Antibodies Therapy Market are Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech, MacroGenics, Inc, Genmab, Alphamab Co. Ltd, Akeso, Inc.

What are the Application segmentation covered in the Bi-Specific Antibodies Therapy Market report?

Ans: The Applications covered in the Bi-Specific Antibodies Therapy Market report are Cancer, Haemophilia, Other Non-Cancer Diseases

What are the Type segmentation covered in the Bi-Specific Antibodies Therapy Market report?

Ans: The Types covered in the Bi-Specific Antibodies Therapy Market report are Fragment-Based Antibodies, IgG-Based Antibodies

1 Study Coverage

1.1 Bi-Specific Antibodies Therapy Product Introduction

1.2 Market by Type

1.2.1 Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (2019 VS 2023 VS 2030)

1.2.2 Fragment-Based Antibodies

1.2.3 IgG-Based Antibodies

1.3 Market by Application

1.3.1 Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Application (2019 VS 2023 VS 2030)

1.3.2 Cancer

1.3.3 Haemophilia

1.3.4 Other Non-Cancer Diseases

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Bi-Specific Antibodies Therapy Market Size Estimates and Forecasts

2.2 Bi-Specific Antibodies Therapy Market Size by Region: 2023 Versus 2030

2.2.1 Global Bi-Specific Antibodies Therapy Revenue by Region: 2019-2024

2.2.2 Global Bi-Specific Antibodies Therapy Revenue Forecast by Region (2025-2030)

2.2.3 Global Bi-Specific Antibodies Therapy Revenue Market Share by Region (2019-2030)

3 Global Bi-Specific Antibodies Therapy by Company

3.1 Global Bi-Specific Antibodies Therapy Revenue by Company (2019-2024)

3.2 Global Bi-Specific Antibodies Therapy Revenue Share by Company (2019-2024)

3.3 Competitive Landscape

3.3.1 Key Bi-Specific Antibodies Therapy Companies around the World: Ranking by Revenue

3.3.2 Global Bi-Specific Antibodies Therapy Market Concentration Ratio (CR5 and HHI) & (2019-2024)

3.3.3 Global Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.4 Global Bi-Specific Antibodies Therapy Companies Headquarters & Product Type

3.4.1 Bi-Specific Antibodies Therapy Companies Headquarters

3.4.2 Global Bi-Specific Antibodies Therapy Companies Product & Service

3.4.3 Date of International Companies Enter into Bi-Specific Antibodies Therapy Market

3.5 Global Bi-Specific Antibodies Therapy Mergers & Acquisitions, Expansion Plans

4 Company Profiles

4.1 Roche

4.1.1 Roche Company Information

4.1.2 Roche Description, Business Overview

4.1.3 Roche Bi-Specific Antibodies Therapy Products Offered

4.1.4 Roche Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.1.5 Roche Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.1.6 Roche Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.1.7 Roche Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.1.8 Roche Recent Developments

4.2 Amgen

4.2.1 Amgen Company Information

4.2.2 Amgen Description, Business Overview

4.2.3 Amgen Bi-Specific Antibodies Therapy Products Offered

4.2.4 Amgen Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.2.5 Amgen Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.2.6 Amgen Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.2.7 Amgen Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.2.8 Amgen Recent Developments

4.3 Sanofi

4.3.1 Sanofi Company Information

4.3.2 Sanofi Description, Business Overview

4.3.3 Sanofi Bi-Specific Antibodies Therapy Products Offered

4.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.3.5 Sanofi Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.3.6 Sanofi Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.3.7 Sanofi Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.3.8 Sanofi Recent Developments

4.4 Pfizer

4.4.1 Pfizer Company Information

4.4.2 Pfizer Description, Business Overview

4.4.3 Pfizer Bi-Specific Antibodies Therapy Products Offered

4.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.4.5 Pfizer Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.4.6 Pfizer Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.4.7 Pfizer Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.4.8 Pfizer Recent Developments

4.5 Johnson & Johnson

4.5.1 Johnson & Johnson Company Information

4.5.2 Johnson & Johnson Description, Business Overview

4.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Products Offered

4.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.5.5 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.5.6 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.5.7 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.5.8 Johnson & Johnson Recent Developments

4.6 AstraZeneca

4.6.1 AstraZeneca Company Information

4.6.2 AstraZeneca Description, Business Overview

4.6.3 AstraZeneca Bi-Specific Antibodies Therapy Products Offered

4.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.6.5 AstraZeneca Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.6.6 AstraZeneca Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.6.7 AstraZeneca Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.6.8 AstraZeneca Recent Development

4.7 AbbVie

4.7.1 AbbVie Company Information

4.7.2 AbbVie Description, Business Overview

4.7.3 AbbVie Bi-Specific Antibodies Therapy Products Offered

4.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.7.5 AbbVie Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.7.6 AbbVie Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.7.7 AbbVie Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.7.8 AbbVie Recent Development

4.8 Lindis Biotech

4.8.1 Lindis Biotech Company Information

4.8.2 Lindis Biotech Description, Business Overview

4.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Products Offered

4.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.8.5 Lindis Biotech Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.8.6 Lindis Biotech Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.8.7 Lindis Biotech Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.8.8 Lindis Biotech Recent Development

4.9 MacroGenics, Inc

4.9.1 MacroGenics, Inc Company Information

4.9.2 MacroGenics, Inc Description, Business Overview

4.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Products Offered

4.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.9.5 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.9.6 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.9.7 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.9.8 MacroGenics, Inc Recent Development

4.10 Genmab

4.10.1 Genmab Company Information

4.10.2 Genmab Description, Business Overview

4.10.3 Genmab Bi-Specific Antibodies Therapy Products Offered

4.10.4 Genmab Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.10.5 Genmab Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.10.6 Genmab Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.10.7 Genmab Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.10.8 Genmab Recent Development

4.11 Alphamab Co. Ltd

4.11.1 Alphamab Co. Ltd Company Information

4.11.2 Alphamab Co. Ltd Description, Business Overview

4.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Products Offered

4.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.11.5 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.11.6 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.11.7 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.11.8 Alphamab Co. Ltd Recent Development

4.12 Akeso, Inc.

4.12.1 Akeso, Inc. Company Information

4.12.2 Akeso, Inc. Description, Business Overview

4.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Products Offered

4.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue and Gross Margin (2019-2024)

4.12.5 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue by Product in 2023

4.12.6 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue by Application in 2023

4.12.7 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue by Geographic Area in 2023

4.12.8 Akeso, Inc. Recent Development

5 Breakdown Data by Type

5.1 Global Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)

5.2 Global Bi-Specific Antibodies Therapy Revenue Forecast by Type (2025-2030)

5.3 Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2030)

6 Breakdown Data by Application

6.1 Global Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)

6.2 Global Bi-Specific Antibodies Therapy Revenue Forecast by Application (2025-2030)

6.3 Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2030)

7 North America

7.1 North America Bi-Specific Antibodies Therapy Market Size YoY Growth 2019-2030

7.2 North America Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2019-2030)

7.3 North America Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)

7.4 North America Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)

8 Asia-Pacific

8.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth 2019-2030

8.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Facts & Figures by Region (2019-2030)

8.3 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)

8.4 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)

9 Europe

9.1 Europe Bi-Specific Antibodies Therapy Market Size YoY Growth 2019-2030

9.2 Europe Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2019-2030)

9.3 Europe Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)

9.4 Europe Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)

10 Latin America

10.1 Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth 2019-2030

10.2 Latin America Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2019-2030)

10.3 Latin America Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)

10.4 Latin America Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)

11 Middle East and Africa

11.1 Middle East and Africa Bi-Specific Antibodies Therapy Market Size YoY Growth 2019-2030

11.2 Middle East and Africa Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2019-2030)

11.3 Middle East and Africa Bi-Specific Antibodies Therapy Revenue by Type (2019-2024)

11.4 Middle East and Africa Bi-Specific Antibodies Therapy Revenue by Application (2019-2024)

12 Supply Chain and Sales Channel Analysis

12.1 Bi-Specific Antibodies Therapy Supply Chain Analysis

12.2 Bi-Specific Antibodies Therapy Key Raw Materials and Upstream Suppliers

12.3 Bi-Specific Antibodies Therapy Clients Analysis

12.4 Bi-Specific Antibodies Therapy Sales Channel and Sales Model Analysis

12.4.1 Bi-Specific Antibodies Therapy Distribution Channel Analysis: Indirect Sales VS Direct Sales

12.4.2 Bi-Specific Antibodies Therapy Distribution Channel Analysis: Online Sales VS Offline Sales

12.4.3 Bi-Specific Antibodies Therapy Distributors

13 Market Dynamics

13.1 Bi-Specific Antibodies Therapy Industry Trends

13.2 Bi-Specific Antibodies Therapy Market Drivers

13.3 Bi-Specific Antibodies Therapy Market Challenges

13.4 Bi-Specific Antibodies Therapy Market Restraints

14 Research Findings and Conclusion

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Major Companies of Fragment-Based Antibodies

Table 3. Major Companies of IgG-Based Antibodies

Table 4. Global Bi-Specific Antibodies Therapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Bi-Specific Antibodies Therapy Market Size by Region (US$ Million): 2023 VS 2030

Table 6. Global Bi-Specific Antibodies Therapy Revenue by Region (2019-2024) & (US$ Million)

Table 7. Global Bi-Specific Antibodies Therapy Revenue Forecast by Region (2025-2030) & (US$ Million)

Table 8. Bi-Specific Antibodies Therapy Revenue by Company (2019-2024) & (US$ Million)

Table 9. Bi-Specific Antibodies Therapy Revenue Share by Company (2019-2024)

Table 10. Ranking of Global Top Bi-Specific Antibodies Therapy Players by Revenue (US$ Million) in 2023

Table 11. Global Bi-Specific Antibodies Therapy Companies Market Concentration Ratio (CR5 and HHI) & (2019-2024)

Table 12. Global Bi-Specific Antibodies Therapy by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2023)

Table 13. Global Bi-Specific Antibodies Therapy Companies Headquarters

Table 14. Global Bi-Specific Antibodies Therapy Companies Product & Service

Table 15. Date of International Companies Enter into Bi-Specific Antibodies Therapy Market

Table 16. Global Bi-Specific Antibodies Therapy Mergers & Acquisitions, Expansion Plans

Table 17. Roche Company Information

Table 18. Roche Description and Business Overview

Table 19. Roche Bi-Specific Antibodies Therapy Product

Table 20. Roche Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 21. Roche Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 22. Roche Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 23. Roche Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 24. Roche Recent Development

Table 25. Amgen Company Information

Table 26. Amgen Description and Business Overview

Table 27. Amgen Bi-Specific Antibodies Therapy Product

Table 28. Amgen Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 29. Amgen Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 30. Amgen Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 31. Amgen Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 32. Amgen Recent Development

Table 33. Sanofi Company Information

Table 34. Sanofi Description and Business Overview

Table 35. Sanofi Bi-Specific Antibodies Therapy Product

Table 36. Sanofi Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 37. Sanofi Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 38. Sanofi Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 39. Sanofi Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 40. Sanofi Recent Development

Table 41. Pfizer Company Information

Table 42. Pfizer Description and Business Overview

Table 43. Pfizer Bi-Specific Antibodies Therapy Product

Table 44. Pfizer Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 45. Pfizer Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 46. Pfizer Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 47. Pfizer Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 48. Pfizer Recent Development

Table 49. Johnson & Johnson Company Information

Table 50. Johnson & Johnson Description and Business Overview

Table 51. Johnson & Johnson Bi-Specific Antibodies Therapy Product

Table 52. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 53. Johnson & Johnson Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 54. Johnson & Johnson Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 55. Johnson & Johnson Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 56. Johnson & Johnson Recent Development

Table 57. AstraZeneca Company Information

Table 58. AstraZeneca Description and Business Overview

Table 59. AstraZeneca Bi-Specific Antibodies Therapy Product

Table 60. AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 61. AstraZeneca Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 62. AstraZeneca Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 63. AstraZeneca Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 64. AstraZeneca Recent Development

Table 65. AbbVie Company Information

Table 66. AbbVie Description and Business Overview

Table 67. AbbVie Bi-Specific Antibodies Therapy Product

Table 68. AbbVie Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 69. AbbVie Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 70. AbbVie Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 71. AbbVie Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 72. AbbVie Recent Development

Table 73. Lindis Biotech Company Information

Table 74. Lindis Biotech Description and Business Overview

Table 75. Lindis Biotech Bi-Specific Antibodies Therapy Product

Table 76. Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 77. Lindis Biotech Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 78. Lindis Biotech Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 79. Lindis Biotech Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 80. Lindis Biotech Recent Development

Table 81. MacroGenics, Inc Company Information

Table 82. MacroGenics, Inc Description and Business Overview

Table 83. MacroGenics, Inc Bi-Specific Antibodies Therapy Product

Table 84. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 85. MacroGenics, Inc Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 86. MacroGenics, Inc Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 87. MacroGenics, Inc Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 88. MacroGenics, Inc Recent Development

Table 89. Genmab Company Information

Table 90. Genmab Description and Business Overview

Table 91. Genmab Bi-Specific Antibodies Therapy Product

Table 92. Genmab Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 93. Genmab Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 94. Genmab Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 95. Genmab Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 96. Genmab Recent Development

Table 97. Alphamab Co. Ltd Company Information

Table 98. Alphamab Co. Ltd Description and Business Overview

Table 99. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product

Table 100. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 101. Alphamab Co. Ltd Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 102. Alphamab Co. Ltd Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 103. Alphamab Co. Ltd Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 104. Alphamab Co. Ltd Recent Development

Table 105. Akeso, Inc. Company Information

Table 106. Akeso, Inc. Description and Business Overview

Table 107. Akeso, Inc. Bi-Specific Antibodies Therapy Product

Table 108. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$ Million) and Gross Margin (2019-2024)

Table 109. Akeso, Inc. Revenue Proportion of Bi-Specific Antibodies Therapy by Product in 2023

Table 110. Akeso, Inc. Revenue Proportion of Bi-Specific Antibodies Therapy by Application in 2023

Table 111. Akeso, Inc. Revenue Proportion of Bi-Specific Antibodies Therapy by Geographic Area in 2023

Table 112. Akeso, Inc. Recent Development

Table 113. Global Bi-Specific Antibodies Therapy Revenue by Type (2019-2024) & (US$ Million)

Table 114. Global Bi-Specific Antibodies Therapy Revenue Forecast by Type (2025-2030) & (US$ Million)

Table 115. Global Bi-Specific Antibodies Therapy Revenue by Application (2019-2024) & (US$ Million)

Table 116. Global Bi-Specific Antibodies Therapy Revenue Forecast by Application (2025-2030) & (US$ Million)

Table 117. North America Bi-Specific Antibodies Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 118. North America Bi-Specific Antibodies Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 119. North America Bi-Specific Antibodies Therapy Revenue by Type (2019-2024) & (US$ Million)

Table 120. North America Bi-Specific Antibodies Therapy Revenue by Application (2019-2024) & (US$ Million)

Table 121. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Region (2019-2030) & (US$ Million)

Table 122. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Region (2025-2030) & (US$ Million)

Table 123. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Type (2019-2024) & (US$ Million)

Table 124. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Application (2019-2024) & (US$ Million)

Table 125. Europe Bi-Specific Antibodies Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 126. Europe Bi-Specific Antibodies Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 127. Europe Bi-Specific Antibodies Therapy Revenue by Type (2019-2024) & (US$ Million)

Table 128. Europe Bi-Specific Antibodies Therapy Revenue by Application (2019-2024) & (US$ Million)

Table 129. Latin America Bi-Specific Antibodies Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 130. Latin America Bi-Specific Antibodies Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 131. Latin America Bi-Specific Antibodies Therapy Revenue by Type (2019-2024) & (US$ Million)

Table 132. Latin America Bi-Specific Antibodies Therapy Revenue by Application (2019-2024) & (US$ Million)

Table 133. Middle East and Africa Bi-Specific Antibodies Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 134. Middle East and Africa Bi-Specific Antibodies Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 135. Middle East and Africa Bi-Specific Antibodies Therapy Revenue by Type (2019-2024) & (US$ Million)

Table 136. Middle East and Africa Bi-Specific Antibodies Therapy Revenue by Application (2019-2024) & (US$ Million)

Table 137. Bi-Specific Antibodies Therapy Key Raw Materials, Industry Status and Trend

Table 138. Bi-Specific Antibodies Therapy Key Raw Materials and Upstream Suppliers

Table 139. Bi-Specific Antibodies Therapy Clients Status and Trend

Table 140. Bi-Specific Antibodies Therapy Typical Clients

Table 141. Bi-Specific Antibodies Therapy Distributors

Table 142. Bi-Specific Antibodies Therapy Market Trends

Table 143. Bi-Specific Antibodies Therapy Market Drivers

Table 144. Bi-Specific Antibodies Therapy Market Challenges

Table 145. Bi-Specific Antibodies Therapy Market Restraints

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

List of Figures

Figure 1. Bi-Specific Antibodies Therapy Product Picture

Figure 2. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type in 2023 & 2030

Figure 3. Fragment-Based Antibodies Product Picture

Figure 4. IgG-Based Antibodies Product Picture

Figure 5. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application in 2023 & 2030

Figure 6. Cancer

Figure 7. Haemophilia

Figure 8. Other Non-Cancer Diseases

Figure 9. Bi-Specific Antibodies Therapy Report Years Considered

Figure 10. Global Bi-Specific Antibodies Therapy Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Bi-Specific Antibodies Therapy Market Size 2019-2030 (US$ Million)

Figure 12. Global Bi-Specific Antibodies Therapy Market Size Market Share by Region: 2023 Versus 2030

Figure 13. Global Bi-Specific Antibodies Therapy Revenue Market Share by Region (2019-2030)

Figure 14. Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 15. Global Bi-Specific Antibodies Therapy Revenue Market Share Forecast by Type (2019-2030)

Figure 16. Global Bi-Specific Antibodies Therapy Revenue Market Share Forecast by Application (2019-2030)

Figure 17. North America Bi-Specific Antibodies Therapy Revenue 2019-2030 (US$ Million)

Figure 18. North America Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2024)

Figure 19. North America Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2024)

Figure 20. Asia-Pacific Bi-Specific Antibodies Therapy Revenue 2019-2030 (US$ Million)

Figure 21. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Share by Region (2019-2030)

Figure 22. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2024)

Figure 23. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2024)

Figure 24. Europe Bi-Specific Antibodies Therapy Revenue Growth Rate 2019-2030 (US$ Million)

Figure 25. Europe Bi-Specific Antibodies Therapy Revenue Market Share by Country (2019-2030)

Figure 26. Europe Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2024)

Figure 27. Europe Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2024)

Figure 28. Latin America Bi-Specific Antibodies Therapy Revenue Growth Rate 2019-2030 (US$ Million)

Figure 29. Latin America Bi-Specific Antibodies Therapy Revenue Market Share by Country (2019-2024)

Figure 30. Latin America Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2024)

Figure 31. Latin America Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2024)

Figure 32. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Growth Rate 2019-2030 (US$ Million)

Figure 33. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Country (2019-2030)

Figure 34. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2024)

Figure 35. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2024)

Figure 36. Bi-Specific Antibodies Therapy Supply Chain (Upstream and Downstream Market)

Figure 37. Global Production Market Share of Bi-Specific Antibodies Therapy Raw Materials by Region in 2023

Figure 38. Bi-Specific Antibodies Therapy Distribution Channels

Figure 39. Global Bi-Specific Antibodies Therapy Percentage 2019-2030: Indirect Sales VS Direct Sales

Figure 40. Global Bi-Specific Antibodies Therapy Percentage 2019-2030: Online Sales VS Offline Sales

Figure 41. Bottom-up and Top-down Approaches for This Report

Figure 42. Data Triangulation

Figure 43. Key Executives Interviewed

Figure 44. Global Bi-Specific Antibodies Therapy Percentage 2019-2030: Online Sales VS Offline Sales

Figure 45. Bottom-up and Top-down Approaches for This Report

Figure 46. Data Triangulation

Figure 47. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$5900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions